Home to the country’s top psychiatrists who are leading the field in patient care, research, and medical education.
Last year, we provided care for 20,000 patients and trained 100 residents. Our academic partners — Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons — are consistently ranked No. 1 in NIH funding. With nationally recognized psychiatrists and psychologists across two academic medical center campuses, we can offer robust specialized programs, such as Addiction & Substance Use Rehabilitation, Geriatric Psychiatry, and Ketamine therapy, to respond to our community’s needs.
Assessing Brain Connectivity Patterns and Treatment Response in OCD
A Columbia psychiatrist examines how resting-state functional connectivity and cognitive control predict symptom improvement with exposure and response prevention in adults and adolescents with obsessive compulsive disorder.
Examining the Connection Between COVID-19 and Cognitive Deficits
Weill Cornell Medicine neuropsychology faculty receive the Neuropsychopharmacology Editors' Award for a Transformative Original Report for their paper, Frequency and Profile of Objective Cognitive Deficits in Hospitalized Patients Recovering from COVID-19.
Crossword Puzzles Beat Computerized Games in Slowing Memory Loss
A Columbia psychiatrist conducts research that finds adults with mild cognitive decline assigned crossword puzzles demonstrated greater cognitive improvement than those who were trained on cognitive video games.
Preventing Suicide on a Worldwide Scale
At Columbia, Dr. Kelly Posner, a leading scientist in the development of the Columbia-Suicide Severity Rating Scale, shares the message about the impact of this simple, yet potent screening tool.
Cannabis Use Disorder Rising Significantly During Pregnancy
Columbia and Weill Cornell Medicine researchers report their findings in JAMA Psychiatry that cannabis use disorders increased 150 percent in prenatal hospitalizations from 2010 to 2018.
Expanding Research in Personalized Treatments for Depression
Weill Cornell Medicine receives a three-year grant to further develop targeted approaches, such as transcranial magnetic stimulation, for the treatment of refractory depression.
Weathering the Storm: Emotion Regulation App Aids in Suicide Prevention
Weill Cornell Medicine psychologists and psychiatrists develop a psychosocial intervention for middle-aged and older adults at high suicidal risk to bring therapy to them outside of formal therapy sessions.
Exploring the Potential of Psychedelic Therapy to Improve Depressive Symptoms
Columbia psychiatrists take part in a phase 2b clinical trial of psilocybin – a psychedelic compound in magic mushrooms.
Mobile Depression App Provides Point-of-Care Treatment Algorithms
Columbia Psychiatry faculty have developed an interactive smartphone application to strengthen clinicians’ ability to provide outpatient mental health services.
Stephen Kanne, PhD Brings Innovative Approaches to Autism Care at CADB
Spearheaded by Stephen M. Kanne, PhD, the Center for Autism and the Developing Brain blends world-class psychiatry and autism expertise to bring the latest evidence-based approaches to the diagnosis and treatment of ASD.
‘Anxiety Cells’ Identified in the Brain’s Hippocampus
Neuroscientists at Columbia University Medical Center and the University of California, San Francisco, have found in mice that certain brain cells in the hippocampus fire when the animal is anxious, triggering anxiety-related behaviors.
Opioid Overdose Survivors Face Higher Death Rate
Researchers at NewYork-Presbyterian/
Online Databases: A Prescription for the Opioid Epidemic
As drug overdoses continue to rise in the United States, doctors and policymakers search for solutions to stem the tide of opioid-related deaths. Researchers at NewYork-Presbyterian/
Defining Unique Subtypes in Depression
In a quest to better define depression diagnosis, a neuroscientist and psychiatrist at NewYork-Presbyterian/
The Role of Ketamine in Treatment-Resistant Depression
It is estimated that by 2030 depressive illness will account for more disability than any other illness worldwide. Investigators at NewYork-Presbyterian/Columbia are studying the use of ketamine as a treatment option for reducing suicidal thoughts in patients with refractory depression.
Newsletters for Medical Professionals
2022 Issue 1
2021 Issue 2
- Cognitive Flexibility: A New Understanding of the Prefrontal Cortex
- COVID-19: Causative Role in Psychosis, Depression, and Other Mental Health Conditions
2021 Issue 1
- Dr. Vivian Pender: Upcoming President of APA
- Recognizing Safety Signals May Reduce Fear and Anxiety
- Investigating the Neurobiological Mechanism for Hallucinations and Delusions
2020 Issue 1
2019 Issue 1
- Research Highlights: Targeting Challenges in Mental Health
2018 Issue 3
2018 Issue 2
- Dr. Francis Lee Named Chair of Psychiatry at Weill Cornell Medicine
- Promoting New Directions in Suicide Prevention
- Improving Interventions for Mid- and Late-Life Depression
- Borderline Personality Disorder: Presenting a Neuroscience Research Orientation
2018 Issue 1
- Secret Agent Society: Boosting Emotional and Social Skills in Youth
- Mental Health First Aid: Engaging Communities to Improve Access to Quality Service
2017 Issue 2
2017 Issue 1
- Applying Mindfulness Approaches to Stress Reduction
- Tracing and Tagging Memories: Science Fiction Becomes Science Fact